Basic Information
M-M-RVaxPro
Regulatory Information
EMEA/H/C/000604
May 5, 2006
February 23, 2006
34
January 21, 2025
Company Information
the netherlands
Waarderweg 39 2031 BN Haarlem
Merck Sharp & Dohme BV
Active Substances Detail
measles virus Enders’ Edmonston strain (live, attenuated)mumps virus Jeryl Lynn (level B) strain (live, attenuated)rubella virus Wistar RA 27/3 strain (live, attenuated)
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication M-M-RVaxPro is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older. For use in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella.
Overview Summary
This is a summary of the European public assessment report (EPAR) for M-M-RVaxPro. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use M-M-RVaxPro. For practical information about using M-M-RVaxPro, patients should read the package leaflet or contact their doctor or pharmacist.